代谢综合征和糖尿病中的高血压：发病机制、临床研究与治疗
Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment.
作者信息
Izzo Joseph L
机构信息
Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14209, USA.
出版信息
J Clin Hypertens (Greenwich). 2003 Nov-Dec;5(6 Suppl 4):3-10. doi: 10.1111/j.1524-6175.2003.02670.x.
Abstract
The increasing prevalence of obesity, hypertension, and abnormal glucose metabolism is a major challenge to health care in industrialized societies. This brief review summarizes the mechanistic evidence and clinical studies related to the problem of hypertension in the metabolic syndrome and diabetes to allow clinicians to provide more effective and enlightened management of these common, interrelated problems.
摘要
肥胖、高血压和糖代谢异常的患病率不断上升，这是工业化社会医疗保健面临的一项重大挑战。本简要综述总结了与代谢综合征和糖尿病中高血压问题相关的机制证据和临床研究，以便临床医生能够对这些常见的、相互关联的问题提供更有效、更具启发性的管理。
相似文献
1
Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment.代谢综合征和糖尿病中的高血压：发病机制、临床研究与治疗
J Clin Hypertens (Greenwich). 2003 Nov-Dec;5(6 Suppl 4):3-10. doi: 10.1111/j.1524-6175.2003.02670.x.
2
Does the metabolic syndrome make blood pressure control more difficult in diabetes?代谢综合征是否会使糖尿病患者的血压控制更加困难？
J Hypertens. 2005 Dec;23(12):2155-6. doi: 10.1097/01.hjh.0000188730.67969.db.
3
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update.糖尿病和代谢综合征患者的高血压：病理生理学见解与治疗进展
Curr Diab Rep. 2007 Jun;7(3):208-17. doi: 10.1007/s11892-007-0033-3.
4
Targeting hypertension in patients with cardiorenal metabolic syndrome.针对心肾代谢综合征患者的高血压。
Curr Hypertens Rep. 2012 Oct;14(5):397-402. doi: 10.1007/s11906-012-0292-5.
5
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.厄贝沙坦/氢氯噻嗪对患有代谢综合征和2型糖尿病的男性和女性的降压疗效。
J Clin Hypertens (Greenwich). 2006 Jul;8(7):470-80. doi: 10.1111/j.1524-6175.2006.05486.x.
6
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.2型糖尿病患者心血管风险的管理作为心脏代谢综合征的一个组成部分。
J Cardiometab Syndr. 2006 Spring;1(2):133-40. doi: 10.1111/j.1559-4564.2006.05487.x.
7
Management of hypertension in children and adolescents with the metabolic syndrome.患有代谢综合征的儿童和青少年的高血压管理。
J Cardiometab Syndr. 2006 Summer;1(4):259-68. doi: 10.1111/j.1559-4564.2006.05801.x.
8
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.拉丁美洲高血压合并糖尿病和代谢综合征患者管理共识。
J Hypertens. 2019 Jun;37(6):1126-1147. doi: 10.1097/HJH.0000000000002072.
9
Treatment of hypertension in metabolic syndrome: implications of recent clinical trials.代谢综合征中高血压的治疗：近期临床试验的启示
Curr Diab Rep. 2009 Jun;9(3):229-37. doi: 10.1007/s11892-009-0037-2.
10
Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?高血压、代谢综合征与患糖尿病风险：是时候更改指南了吗？
J Clin Hypertens (Greenwich). 2004 Aug;6(8):425-7. doi: 10.1111/j.1524-6175.2004.03751.x.
引用本文的文献
1
Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.奥利司他治疗非酒精性脂肪性肝病肥胖患者的疗效：一项随机对照试验的系统评价和荟萃分析
Proc (Bayl Univ Med Cent). 2024 Apr 9;37(4):603-612. doi: 10.1080/08998280.2024.2335829. eCollection 2024.
本文引用的文献
1
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies.圣安东尼奥心脏研究和弗雷明汉后代研究中代谢综合征的患病率及特征
Diabetes. 2003 Aug;52(8):2160-7. doi: 10.2337/diabetes.52.8.2160.
2
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.美国国家高血压预防、检测、评估与治疗联合委员会第七次报告：JNC 7报告。
JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14.
3
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.美国国家健康和营养检查调查（NHANES）III中50岁及以上参与者的美国国家胆固醇教育计划（NCEP）定义的代谢综合征、糖尿病及冠心病患病率。
Diabetes. 2003 May;52(5):1210-4. doi: 10.2337/diabetes.52.5.1210.
4
Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods.胰岛素抵抗与内脏肥胖的遗传流行病学。IRAS家族研究的设计与方法。
Ann Epidemiol. 2003 Apr;13(4):211-7. doi: 10.1016/s1047-2797(02)00412-x.
5
Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention?慢性肾脏病中的血流动力学心血管危险因素：干预措施有哪些效果？
Semin Dial. 2003 Mar-Apr;16(2):128-39. doi: 10.1046/j.1525-139x.2003.16029.x.
6
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.2型糖尿病患者的多因素干预与心血管疾病
N Engl J Med. 2003 Jan 30;348(5):383-93. doi: 10.1056/NEJMoa021778.
7
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.特定年龄的正常血压与血管性死亡率的相关性：对61项前瞻性研究中100万成年人个体数据的荟萃分析
Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8.
8
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).高危高血压患者随机接受血管紧张素转换酶抑制剂或钙通道阻滞剂与利尿剂治疗的主要结局：抗高血压和降脂治疗预防心脏病发作试验（ALLHAT）
JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981.
9
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.血管紧张素 II 诱导的胰岛素抵抗与胰岛素信号增强有关。
Hypertension. 2002 Dec;40(6):872-9. doi: 10.1161/01.hyp.0000040262.48405.a8.
10
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.氯沙坦干预降低高血压终点事件研究（LIFE）中糖尿病患者的心血管发病率和死亡率：一项与阿替洛尔对比的随机试验
Lancet. 2002 Mar 23;359(9311):1004-10. doi: 10.1016/S0140-6736(02)08090-X.
Zotero 插件